Welcome to AstraZeneca United States
Beginning its journey in 1953, AstraZeneca became one of the first pharmaceutical companies operating in the United States
Latest News from AstraZeneca United States
TAGRISSO® (osimertinib) receives US FDA full approval
Conversion from accelerated to full approval confirms the potential of TAGRISSO to become a standard of care for patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer whose disease has progressed on or after EGFR-TKI therapy
Approval based on Phase III AURA3 trial that demonstrated significant improvement in progression-free survival with TAGRISSO as compared to chemotherapy
New data demonstrate RSV immunoprophylaxis with SYNAGIS® (palivizumab) may result in reduced overall costs in preterm infants born at 29-32 wGA who are less than three months of age
New health economic study for SYNAGIS (palivizumab) presented at the Academy of Managed Care Pharmacy Annual Meeting 2017
AstraZeneca today announced new results data which evaluated the cost-effectiveness of SYNAGIS® (palivizumab) for respiratory syncytial virus (RSV) in preterm infants 29-34 weeks gestational age compared to those who did not receive SYNAGIS.
AstraZeneca shares progress on LYNPARZA™ (olaparib) tablets in the US
FDA Grants Priority Review for Maintenance Setting in Ovarian Cancer Patients with PDUFA Set for Q3 2017
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for LYNPARZA™ (olaparib) tablets (300mg twice daily) for use in platinum-sensitive, relapsed ovarian cancer patients in the maintenance setting.
AstraZeneca’s CVD-REAL study shows SGLT-2 inhibitors significantly reduced hospitalizations for heart failure and death versus other type-2 diabetes medicines
Landmark real-world evidence from an international study of more than 300,000 patients with type-2 diabetes showed treatment with SGLT-2 inhibitors reduced risk of hospitalization for heart failure by 39% and all-cause mortality by 51%
CVD-REAL data are presented at the American College of Cardiology 66th Annual Scientific Session
Latest AZ&You Blog Articles
Supporting Patients and Communities: Our 2016 Corporate Responsibility at a Glance
Everything we do at AstraZeneca is driven by our commitment to improving the lives of patients, and part of that involves our corporate responsibility efforts to support healthy, vibrant communities beyond our medicines.
The Power of Us: Employees’ Community Impact in 2016
AstraZeneca has a long history of community service and a strong commitment to making a meaningful difference for patients and communities beyond our medicines through our corporate responsibility activities. In addition to our corporate efforts, our Power of Us program empowers employees to give back in two ways: by providing paid time off to volunteer with nonprofit organizations of their choice, as well as by matching their charitable donations.
Our Favorites from 2016 – Highlights of the AZ&You Blog
Throughout 2016 on our blog, we shared interviews with patients; news about partnerships and initiatives that help support patients and science; stories that illustrate our focus on advancing patient health and access to care; and much more. From the dozens of blog posts we published this year, we put together a list of some of our favorites that we want to make sure you catch before the year is over.
Stigma, Genetics and Hope: 11 Years with Lung Cancer
In 2005, Melissa Crouse was diagnosed with lung cancer and given three to five years to live. Eleven years later, Melissa continues to manage her disease while giving back to the lung cancer community and getting the most out of life. Melissa shares her perspective on living with lung cancer, understanding the importance of biomarkers, and remaining hopeful.
What Does the New CancerLinQ Discovery Initiative Mean for the Future of Patient Care?
By Kevin Fitzpatrick, CEO, CancerLinQ LLC
This is an exciting time in the field of oncology—a time of rapid discovery, learning and new treatments to fight this terrible disease, as we work to provide patients with greater hope. Imagine taking these daily learnings and aggregating them in one accessible place while simultaneously creating a learning platform that medical oncologists can use to help improve patient care.
Personalized Healthcare: What It Means and Why It Matters
When it comes to cancer treatment, one size does not fit all. Of the estimated 1.6 million Americans who will be diagnosed with cancer in 2016, no two will be exactly the same. More and more, we’re hearing (and using) buzzwords to this effect: Personalized healthcare. Precision medicine. Targeted therapy.
If you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.